A carregar...
Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series
Alemtuzumab—a monoclonal antibody targeting the CD52 glycoprotein expressed by most mature leucocytes—effectively decreases relapse rate and disability progression in early, relapsing–remitting multiple sclerosis (MS). However, secondary autoimmune disorders complicate therapy in nearly 50% of treat...
Na minha lista:
| Publicado no: | Eye (Lond) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6367353/ https://ncbi.nlm.nih.gov/pubmed/30498266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-018-0282-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|